Status:
COMPLETED
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Lead Sponsor:
Asan Medical Center
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regi...
Detailed Description
Patients should have been treated with bevacizumab plus chemotherapy as a 1st line treatment, and after 1st progression, these patients will be accrued in this study of bevacizumab plus chemotherapy a...
Eligibility Criteria
Inclusion
- Histologically documented colorectal adenocarcinoma
- Progression during first-line bevacizumab containing chemotherapy within 3 months
- No serious toxicity to bevacizumab of 1st line treatment
- Unresectable metastases
- Uni-dimensional measurable lesion(s) by RECIST
- Age over 18 years old
- ECOG 0-2
- Adequate organ functions by clinical laboratory exams
Exclusion
- Other tumor type than adenocarcinoma
- CNS metastases
- GI bleeding
- Hypersensitivity to any of chemotherapeutic agents
- Prior use of cetuximab or other targeted agents other than bevacizumab
- Major surgery within 6 weeks
- Other serious illness
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT00862342
Start Date
January 1 2009
End Date
June 1 2012
Last Update
July 17 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, Songpa-gu, South Korea